(E)-N’-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide protecting rat heart tissues from isoproterenol toxicity: Evidence from in vitro and in vivo tests

The current study was aimed to assess the protective effect of a new molecule (E)-N’-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide, denoted 1c, against cardiac remodeling process in isoproterenol (Isop) induced myocardial infarction (MI) in rats. Male Wistar rats were randomly divided...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:European journal of pharmacology Ročník 881; s. 173137
Hlavní autoři: Khdhiri, Emna, Mnafgui, Kais, Ghazouani, Lakhdar, Feriani, Anouar, Hajji, Raouf, Bouzanna, Walid, Allouche, Noureddine, Bazureau, Jean-Pierre, Ammar, Houcine, Abid, Souhir
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands Elsevier B.V 15.08.2020
Elsevier
Témata:
(E)-N’-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide
ACE
Action Potentials - drug effects
Angiotensin-Converting Enzyme Inhibitors - chemical synthesis
Angiotensin-Converting Enzyme Inhibitors - pharmacology
Animals
Anti-Inflammatory Agents - chemical synthesis
Anti-Inflammatory Agents - pharmacology
Biomarkers - blood
Cardiotoxicity
Chemical Sciences
Disease Models, Animal
Fibrinogen - metabolism
Fibrinolytic Agents - chemical synthesis
Fibrinolytic Agents - pharmacology
Heart Rate - drug effects
Hydrazones - chemical synthesis
Hydrazones - pharmacology
Isoproterenol
Life Sciences
Lipids - blood
Male
Myocardial infarction
Myocardial Infarction - chemically induced
Myocardial Infarction - metabolism
Myocardial Infarction - physiopathology
Myocardial Infarction - prevention & control
Myocytes, Cardiac - drug effects
Myocytes, Cardiac - metabolism
Myocytes, Cardiac - pathology
Necrosis
Rats, Wistar
Thrombolytic
Ventricular Remodeling - drug effects
Myocardial infarction
Thrombolytic
ACE
(E)-N’-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide
Isoproterenol
E)-N’-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide
ISSN:0014-2999, 1879-0712, 1879-0712, 0014-2999
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The current study was aimed to assess the protective effect of a new molecule (E)-N’-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide, denoted 1c, against cardiac remodeling process in isoproterenol (Isop) induced myocardial infarction (MI) in rats. Male Wistar rats were randomly divided into four groups, control, Isop (85 mg/kg body weight was injected subcutaneously into rats at an interval of 24 h for 2 days (6th and 7th day) to induce MI and pretreated animals with acenocoumarol (Ace) (150 μg/kg bw) and 1c (150 μg/kg bw) by oral administration during 7 days and injected with isoproterenol (Isop + Ace) and (Isop + 1c) groups. Results in vitro showed that 1c is endowed with potent inhibition of angiotensin-converting enzyme (ACE) with an IC50 39.12 μg/ml. The in vivo exploration evidenced alteration in the ECG pattern, notable cardiac hypertrophy and increase in plasma level of fibrinogen, troponin-T, CK-MB and LDH, AST and ALT by 171%, 300%, 50%, 64% and 75% respectively with histological myocardium necrosis and cells inflammatory infiltration. However, pre-treatment with 1c improved the ECG pattern reduced significantly the cardiac dysfunction markers and ameliorated the thrombolytic process by decreasing fibrinogen level as compared to untreated infracted rats. Overall, (E)-N’-(1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene)benzohydrazide 1c could be used as anticoagulant agent to prevent thrombosis in acute myocardial infarction. [Display omitted] •Synthesis of new (E)- N'-[1-(3-oxo-3H-benzo[f]chromen-2-yl)ethylidene benzohydrazide 1c.•In vitro tests showed potent inhibition of angiotensine I-converting enzyme (ACE).•In vivo assays (on rats), pre-treatment with 1c improved the ECG pattern.•1c reduced the cardiac dysfunction markers and ameliorated the thrombolytic process.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0014-2999
1879-0712
1879-0712
0014-2999
DOI:10.1016/j.ejphar.2020.173137